Sionna Therapeutics (NASDAQ:SION) Stock Price Up 6.5% – Here’s What Happened

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price was up 6.5% during trading on Tuesday . The stock traded as high as $40.43 and last traded at $41.3360. Approximately 97,874 shares were traded during trading, a decline of 72% from the average daily volume of 349,595 shares. The stock had previously closed at $38.83.

Analysts Set New Price Targets

Several brokerages recently weighed in on SION. Guggenheim lifted their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Wedbush started coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price target on the stock. JonesTrading boosted their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sionna Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Trading Up 7.8%

The stock has a market cap of $1.89 billion, a P/E ratio of -21.59 and a beta of 1.30. The stock’s 50-day moving average is $39.89 and its 200-day moving average is $39.44.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, equities analysts forecast that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Buying and Selling

In related news, Director Peter A. Thompson sold 235,863 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the sale, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the sale, the director owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,717,962 shares of company stock worth $77,571,889 in the last quarter. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SION. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics in the third quarter worth about $30,000. BNP Paribas Financial Markets bought a new position in shares of Sionna Therapeutics during the 2nd quarter valued at about $31,000. GF Fund Management CO. LTD. acquired a new position in shares of Sionna Therapeutics in the 4th quarter worth approximately $36,000. Balyasny Asset Management L.P. acquired a new position in shares of Sionna Therapeutics in the 4th quarter worth approximately $58,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the 4th quarter worth approximately $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.